The Effect of Prophylactic Use of NSAIDs on Acute Phase Reactions Induced by First-Time Zoledronic Acid Treatment for Osteoporosis

Abstract

Background:

Zoledronic acid is a first-line treatment for primary osteoporosis, but its high acute-phase-reaction (APR) incidence can reduce patient compliance and long-term efficacy. Non-steroidal anti-inflammatory drugs (NSAIDs), with antipyretic and analgesic effects, can relieve APR symptoms like fever and muscle soreness caused by zoledronic acid. However, the role of prophylactic NSAID use in decreasing APRs remains controversial.

Objective:

This study aims to evaluate the impact of NSAIDs on preventing zoledronic acid-related APRs to guide clinical practice.

Methods:

Retrospective data of osteoporosis patients receiving zoledronic acid injection at Shenzhen University General Hospital from January 2023 to December 2024 were collected. A 1:2 propensity score matching (PSM) compared the APR incidences between the non-NSAIDs and NSAIDs groups.

Results:

Among 351 cases (98 non-NSAIDs, 253 NSAIDs), 200 cases (79 non-NSAIDs, 121 NSAIDs) remained after PSM. The NSAIDs group had a lower overall APR incidence (38.0% vs. 53.2%, χ² = 4.451, P = .035). There was no significant difference in fever incidence (χ2 = 1.888, P = .169), but pain incidence was lower in the NSAIDs group (25.3% vs. 9.9%, χ² = 8.433, P = .004). Flurbiprofen axetil, ibuprofen, and etoricoxib showed similar APR—preventive effects.

Conclusion and relevance:

Prophylactic NSAIDs significantly reduce zoledronic acid-induced APRs, especially pain, but have no significant effect on preventing fever. The 3 NSAIDs also have comparable efficacy.

Keywords

zoledronic acid nonsteroidal anti-inflammatory drugs acute-phase-reaction primary osteoporosis

Get full access to this article

View all access options for this article.

References

Dennison

Cole

Cooper

Diagnosis and epidemiology of osteoporosis. Curr Opin Rheumatol. 2005;17:456-461. doi:10.1097/01.bor.0000166384.80777.0d

Hasserius

Karlsson

Jónsson

Redlund-Johnell

Johnell

Long-term morbidity and mortality after a clinically diagnosed vertebral fracture in the elderly–a 12- and 22-year follow-up of 257 patients. Calcif Tissue Int. 2005;76(4):235-242. doi:10.1007/s00223-004-2222-2

Office of the Surgeon G. Reports of the Surgeon General. Bone Health and Osteoporosis: A Report of the Surgeon General. Office of the Surgeon General (US); 2004.

GBD 2019 Fracture Collaborators. Global, regional, and national burden of bone fractures in 204 countries and territories, 1990-2019: a systematic analysis from the Global Burden of Disease Study 2019. Lancet Healthy Longev. 2021;2(9):e580-e592. doi:10.1016/s2666-7568(21)00172-0

Qaseem

Hicks

Etxeandia-Ikobaltzeta

, et al. Pharmacologic treatment of primary osteoporosis or low bone mass to prevent fractures in adults: a living clinical guideline from the American College of Physicians. Ann Intern Med. 2023;176:224-238. doi:10.7326/m22-1034

Wang

Zeng

Efficacy and safety of annual infusion of zoledronic acid and weekly oral alendronate in the treatment of primary osteoporosis: a meta-analysis. J Clin Pharmacol. 2023;63(4):455-465. doi:10.1002/jcph.2181

Reid

Gamble

Mesenbrink

Lakatos

Black

DM.

Characterization of and risk factors for the acute-phase response after zoledronic acid. J Clin Endocrinol Metab. 2010;95(9):4380-4387. doi:10.1210/jc.2010-0597

Zhang

Wang

Xue

Zhang

HC.

Early side effects of zoledronic acid in treating postmenopausal osteoporosis. Chin J New Drugs. 2011;20:757-760.

Lee

Nho

Koo

KH.

Persistence with intravenous zoledronate in elderly patients with osteoporosis. Osteoporos Int. 2012;23(9):2329-2333. doi:10.1007/s00198-011-1881-x

10.

Shi

Gong

Zhang

The impact of acute-phase reaction on mortality and re-fracture after zoledronic acid in hospitalized elderly osteoporotic fracture patients. Osteoporos Int. 2023;34(9):1613-1623. doi:10.1007/s00198-023-06803-w

11.

Ding

Zeng

Yin

, et al. Multicenter study on observation of acute-phase responses after infusion of zoledronic acid 5 mg in Chinese women with postmenopausal osteoporosis. Orthop Surg. 2017;9(3):284-289. doi:10.1111/os.12338

12.

Okimoto

Sakai

Yoshioka

, et al. Efficacy of non-steroidal anti-inflammatory drugs on zoledronic acid-induced acute-phase reactions: randomized, open-label, Japanese OZ study. J Bone Miner Metab. 2020;38(2):230-239. doi:10.1007/s00774-019-01050-8

13.

World Health Organization. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group. World Health Organ Tech Rep Ser. 1994;843:1-129. doi:10.1359/jbmr.070906

14.

Recker

Delmas

Halse

, et al. Effects of intravenous zoledronic acid once yearly on bone remodeling and bone structure. J Bone Miner Res. 2008;23(1):6-16. doi:10.1359/jbmr.070906

15.

Shi

Gong

Shao

Predicting the acute-phase response fever risk in bisphosphonate-naive osteoporotic patients receiving their first dose of zoledronate. Osteoporos Int. 2022;33(11):2381-2396. doi:10.1007/s00198-022-06493-w

16.

Zheng

Zhan

, et al. Prediction of musculoskeletal pain after the first intravenous zoledronic acid injection in patients with primary osteoporosis: development and evaluation of a new nomogram. BMC Musculoskelet Disord. 2023;24:841. doi:10.1186/s12891-023-06965-y

17.

Liu

Han

, et al. Reduction effect of oral pravastatin on the acute phase response to intravenous zoledronic acid: protocol for a real-world prospective, placebo-controlled trial. BMJ Open. 2022;12:e060703. doi:10.1136/bmjopen-2021-060703

18.

Black

Delmas

Eastell

, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007;356:1809-1822. doi:10.1056/NEJMoa067312

19.

Lyles

Colón-Emeric

Magaziner

, et al. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med. 2007;357:1799-1809. doi:10.1056/NEJMoa074941

20.

Rogers

Crockett

Coxon

Mönkkönen

Biochemical and molecular mechanisms of action of bisphosphonates. Bone. 2011;49(1):34-41. doi:10.1016/j.bone.2010.11.008

21.

Vane

Botting

RM.

Mechanism of action of anti-inflammatory drugs. Scand J Rheumatol Suppl. 1996;102:9-21. doi:10.3109/03009749609097226

22.

FitzGerald

Patrono

The coxibs, selective inhibitors of cyclooxygenase-2. N Engl J Med. 2001;345:433-442. doi:10.1056/nejm200108093450607

23.

Lanza

Chan

Quigley

; Practice Parameters Committee of the American College of Gastroenterology. Guidelines for prevention of NSAID-related ulcer complications. Am J Gastroenterol. 2009;104(3):728-738. doi:10.1038/ajg.2009.115

24.

Lanas

Hunt

Prevention of anti-inflammatory drug-induced gastrointestinal damage: benefits and risks of therapeutic strategies. Ann Med. 2006;38(6):415-428. doi:10.1080/07853890600925843

25.

Murdoch

Mellar

Horne

, et al. Effect of a three-day course of dexamethasone on acute phase response following treatment with zoledronate: a randomized controlled trial. J Bone Miner Res. 2023;38(5):631-638. doi:10.1002/jbmr.4802

26.

Popp

Senn

Curkovic

, et al. Factors associated with acute-phase response of bisphosphonate-naïve or pretreated women with osteoporosis receiving an intravenous first dose of zoledronate or ibandronate. Osteoporos Int. 2017;28:1995-2002. doi:10.1007/s00198-017-3992-5

27.

Crotti

Watts

De Santis

, et al. Acute phase reactions after zoledronic acid infusion: protective role of 25-hydroxycitamin D and previous oral bisphosphonate therapy. Endocr Pract. 2018;24:405-410. doi:10.4158/ep161638.Or